Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
ContraFect Corp logo — ...focused on discovering & developing differentiated biolog...

ContraFect Corp

...focused on discovering & developing differentiated biologic therapies for life-threatening, drug-resistant infections

Founded 2008 United States Yonkers, United States 10 employees Post Ipo Equity Total: $249.07M Biotechnology, Health Care

General Information

Company Name ContraFect Corp
Founded Year 2008
Location United States Yonkers, United States +1
Founders / Decision Makers
Team member
Employees 10
Industries Biotechnology, Health Care
Funding Stage Post Ipo Equity
Social

Get notified when ContraFect Corp moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About ContraFect Corp

ContraFect Corp is a biotechnology company focused on discovering and developing differentiated biologic therapies for life-threatening, drug-resistant infections. The company is addressing the pressing issue of antimicrobial-resistant infections, which account for an estimated 700,000 deaths worldwide annually. Through their platform of direct lytic agents (DLAs), including lysins and amurin peptides, ContraFect aims to combat these infections. Their lead lysin candidate, exebacase, has completed a Phase 2 clinical trial for the treatment of Staph aureus bacteremia and has been granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections. Furthermore, ContraFect is currently studying exebacase in a pivotal Phase 3 clinical study. ContraFect's approach involves leveraging the unique properties of lysins and amurin peptides, which have demonstrated the ability to target antibiotic-resistant organisms such as MRSA and P. aeruginosa, known to cause serious infections such as bacteremia, pneumonia, and osteomyelitis. The company's efforts are particularly significant in the context of the biotechnology and health care industries. In December 2022, ContraFect Corp received a $7.00M investment in Post-IPO Equity. The company's headquarters is in the United States. Overall, ContraFect Corp is poised to make a significant impact in addressing the global challenge of antibiotic-resistant infections through its innovative biologic therapies.

Taxonomy: biologic therapies, drug-resistant infections, direct lytic agents, lysins, amurin peptides, antimicrobial-resistant infections, antibiotic-resistant infections, Phase 2 clinical trial, Phase 3 clinical study, Breakthrough Therapy designation, monoclonal antibodies, multi-drug resistant infections, biotechnology company, Yonkers, New York

Funding Rounds & Investors (14)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 13 Dec 2022
Post-IPO Equity •••••• - 17 Mar 2021
Grant •••••• 1
Investor
20 Jul 2020
Post-IPO Equity •••••• - 21 May 2020
Post-IPO Equity •••••• - 17 Dec 2019

View All 14 Funding Rounds

ContraFect Corp Alternatives & Competitors

ContraFect Corp vs
Biocidium Biopharmaceuticals
Biocidium Biopharmaceuticals Canada

Clinical-stage biopharmaceutical company focused on novel antibiotics, antifungals, and treatments f...

1 employees
Biopharma, Biotechnology
ContraFect Corp vs
ANTABIO
ANTABIO France

Developing Tomorrow's Antibacterials

Series B
25 employees
Biotechnology, Life Sciences
Compare ContraFect Corp vs ANTABIO
ContraFect Corp vs
Destiny Pharma Limited - In Liquidation
Destiny Pharma Limited - In Liquidation United Kingdom

Mark Smith and Stephen Cork were appointed Administrators on 21 August 2024, and act without persona...

Post Ipo Equity
10 employees
Biotechnology, Health Care
Also compare with: ContraFect Corp vs F2G F2G

FAQ About ContraFect Corp

...focused on discovering & developing differentiated biologic therapies for life-threatening, drug-resistant infections
ContraFect Corp was founded in 2008.
ContraFect Corp is headquartered in Yonkers, United States.
ContraFect Corp operates in the following industries: Biotechnology, Health Care.
ContraFect Corp has approximately 10 employees.
ContraFect Corp has completed 14 funding rounds, raising a total of $249.07M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to ContraFect Corp include Biocidium Biopharmaceuticals, ANTABIO, Destiny Pharma Limited - In Liquidation, ChainPeptides Oy, Madam Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ContraFect Corp and Biocidium Biopharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors ContraFect Corp and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy